Bayer's Nexavar gets Chinese nod; Cephalon sues Barr over Fentora patent;

> Bayer and Onyx Pharmaceuticals got approval from Chinese drug regulators to market their Nexavar drug for liver cancer. Report [1]

> Cephalon sued Barr Pharmaceuticals for patent infringement over its Fentora cancer pain drug, after Barr asked the FDA to approve its generic version. Report [2]

> India's Glenmark Pharmaceuticals posted a 101.9 percent increase in fiscal first-quarter profits on strong growth in its generics business. Report [3]

> Watson Pharmaceuticals named Clare Carmichael as senior vice president for human resources, replacing Susan Skara, who retired. Release [4]

> SiCap, an Albany-area company known for its "Sinus Buster" nasal sprays, has been acquired by Dynova Laboratories, a private-equity-funded venture. Report [5]

> In another instance of the industry teaming up with academia, GlaxoSmithKline and Harvard Stem Cell Institute (HSCI) announced that they have signed a five-year, $25 million pact to research and possibly develop stem cell drugs. Report [6]

> New Jersey-based nutraceutical company Integrated Biopharma is spinning off its interest in iBioPharma to form a stand-alone biotech company. Report [7]

> CHMP announced today the recommendation of Bayer's Xarelto, known generically as rivaroxaban. Report [8]

And Finally... Anxiety and depression double the risk of type 2 diabetes in men, a study shows. Report [9]